1. The bridging concept: optimizing dose for phase II/III in Alzheimer's disease;Cutler;Neurodegeneration.,1996
2. Guidelines for conducting bridging studies in Alzheimer disease;Cutler;Alzheimer Dis Assoc Disord.,1998
3. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER) 2004 http://www.fda.gov/OHRMS/DOCKETS/98fr/02d-0320-gdl0002.pdf.
4. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the “bridging study.”;Cutler;Alzheimer Dis Assoc Disord.,1995
5. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study;Cutler;Eur J Clin Pharmacol.,1995